FORT WASHINGTON, Pa., Oct. 14, 2016 /PRNewswire/ -- FMD K&L Inc. (FMD K&L) and iMEDGlobal Corporation (iMEDGlobal) are pleased to announce that they have entered into a merger agreement. FMD K&L is a privately owned Contract Research Organization (CRO) with headquarters in the USA and China. iMEDGlobal is a privately owned CRO with headquarters in the USA and with main delivery centers in India and the Philippines.
The services, clientele, and delivery centers of the companies are complementary in nature, providing alignment towards the same strategic direction. The merger enables the combined entity to realize cost and revenue synergies across operational integration, a broader spectrum of services, an extended customer base, an expanded global presence, and a stronger sales force. It will also be better equipped to create sustainable value for the clients and institute better business focus for the company and the workforce.
By leveraging the joint capabilities across both firms, including FMD K&L's extensive experience in CRO services which include Clinical Operations, Data Management, Biostatistics, Statistical Programming, and eSubmissions/CDISC as well as iMEDGlobal's service inventory across Pharmacovigilance, Regulatory, Toxicology, and Medical Affairs, it enriches the existing service portfolio of the individual firms and will in turn create benefits to our clients, geographies, and markets.
The merger results in a wider geographical coverage with 19 offices across the globe in countries like the USA, UK, Philippines, India, China, South Korea, Japan, Taiwan, and Armenia. The combined entity will have over 1200 employees. It will be able to provide flexibility in delivery and engagement models, coverage in all time zones, and faster access to the local service team. Backed with an in-house multi-lingual workforce, the company will be in a position to extend regional support for global projects, especially in markets which have language dependencies.
"The combined entity will be led by a strong leadership team possessing substantial prowess in the Pharma and CRO industry," says Dr. Xin Ke, CEO, FMD K&L. "Driven by our core values of accountability, innovation, leadership, quality, and partnership, the company will be prepared to expand its operations across the globe. The combined team of leaders share the same vision, culture, and values which will help in the smooth transition and will also be pivotal in propelling the company for monumental performance."
"The merger itself resulted in achieving synergies in terms of better geographical coverage, a stronger talent force, and a more comprehensive service menu for our clients in the life sciences industry," states Dr. Dan Zhang, Executive Chairman, FMD. "Further, the company will be better positioned to take up large-scale projects in new and existing markets."
Mr. Prashanth Visweswaran, Founder and Executive Chairman, iMEDGlobal states, "The merger represents a culmination of business interests to propel the company to the next level. The strategic advantage of complementary businesses will be instrumental in unlocking greater value for worldwide clients, stakeholders, and the employees. As near-term benefits from this merger, we foresee upward trajectories in revenues, global expertise in service delivery, and growth opportunities for our employees."
About FMD K&L
FMD K&L is a Contract Research Organization (CRO) offering data management, biostatistics, statistical programming, CDISC compliant eSubmission, medical writing, and clinical operations to the pharmaceutical, biotechnology, and medical device industries worldwide. In addition, we provide regulatory affairs services in China and South East Asia. We continuously strive to raise the standard of excellence through accuracy and efficiency. This results in high quality output to get our client's drug or medical product approved faster and to improve the lives of patients.
About iMEDGlobal
iMEDGlobal is a global CRO specialized in regulatory affairs, product safety and toxicology, medical affairs and technology, and clinical operations for biopharmaceutical, medical device, and consumer healthcare industries. Headquartered in Princeton, New Jersey, USA, iMEDGlobal has a presence in the USA, UK, India, and Philippines with delivery centers across these areas ensuring fast execution of the services.
Contact:
| Catherine Ditzler |
Gargi Kumari |
| Senior Marketing Manager |
Global Marketing Head |
| FMD K&L |
iMEDGlobal |
| 1-215-283-6035 |
1-609-759-6900 |
SOURCE FMD K&L Inc.
Share this article